CHP
ALXN

Castle Hook Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Castle Hook Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-73,447
Closed -$8.99M – 68
2016
Q4 		$8.99M Buy
+73,447
New +$8.99M 1.99% 16

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Castle Hook Partners's ALXN Position: Q1 2017 in Review

Castle Hook Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 73,447 shares — an estimated $8.99M sold.

Castle Hook Partners first reported a position in ALXN in Q4 2016 and held it in 1 quarter. The position peaked at $8.99M in Q4 2016. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • Castle Hook Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Castle Hook Partners sold 73,447 Alexion Pharmaceuticals shares in Q1 2017, an estimated $8.99M.
  • Castle Hook Partners first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Castle Hook Partners's Alexion Pharmaceuticals position peaked at $8.99M in Q4 2016.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on Castle Hook Partners's 13F filing for Q1 2017, filed 15 May 2017.